🇫🇷🇨🇦🇺🇸 Associate Professor of Urology & Immunology - Mayo Clinic - Basic and Translational Research - Liquid biopsies and next-gen cancer immunotherapies
Minnesota, USA
Joined December 2016
- Tweets992
- Following411
- Followers580
- Likes2.1K
Fabrice Lucien, PhD retweeted
Our newly published theoretical mathematical model of T-cell responses to PD-1 therapy, developed from more than a decade of clinical observations, offers new insights into the mechanisms and dynamics underlying cancer immunotherapy. | Science Advances science.org/doi/10.1126/scia…
Fabrice Lucien, PhD retweeted
Updated LUNAR analysis out in @EUplatinum. Now with a median follow-up of 32 months, exploratory analyses confirm the addition of 177Lu-PNT2002 to SBRT improves polymetastatic PFS (6 or more new lesion), castrate disease-free survival, and CT-based PFS (i.e., conventional MFS) authors.elsevier.com/sd/arti…
Fabrice Lucien, PhD retweeted
After 15 years of our discovery of soluble PD-L1(B7-H1), we finally have a proof of it as a therapeutic target and have a way to specifically remove it in vivo to restore antitumor immunity. businesswire.com/news/home/2…
Looking forward to sharing our progress on EV-based liquid biopsy and learning more on how to integrate computational biology in our work @iscb Great Plains.
Tunneling NanoTubes (TNT) as an effective means for intercellular mRNA transfer in neighboring cells. Much more efficient than EV-mediated transfer.
cell.com/cell-reports/fullte…
ALWAYS validate your reagents with proper controls and don’t trust product sheets or prior publications.
When you see how much cost antibodies nowadays ($500+/100 micrograms), that’s shocking but unfortunately not surprising.
reeserichardson.blog/2026/08…
nature.com/articles/d41586-0…
Fabrice Lucien, PhD retweeted
Closing the night on prostate. From high risk localized disease discussion of best treatment options surgery vs radiation... To the mHSPC question that keeps coming up: who do you intensify, and who can you spare? Biomarkers are starting to answer it. 🎯
#GURounds expertly led by @KSchaffer17 with input from the entire Nashville team @BGarmezy @alantanmd @TomJayram @AKRadDoc @DavidMorrismd
Representation from @VUMCRadOnc @TNOncology @theGHCR @SarahCannonDocs
Fabrice Lucien, PhD retweeted
Our new paper is out! 🎉
In mCRPC treated with PSMA-RLT, metastatic disease volume emerged as a key driver of outcomes.
A simple stratification that could sharpen how we select patients.
Full study 🔗
link.springer.com/article/10…
@JackAndrewsMD @MayoRadiology @MayoUrology
Fabrice Lucien, PhD retweeted
I’m pleased to share Mayo Clinic has announced a strategic collaboration with @Microsoft to develop and deploy a frontier AI model designed specifically for healthcare. Read more: newsnetwork.mayoclinic.org/d…
Fabrice Lucien, PhD retweeted
Brilliant discussant slide from @CalaisJeremie putting into context the results from AcTION and CONV01-alpha with PSMAddition and VISION
@urotoday #ASCO26
Exciting work on EV-based biomarkers in advanced prostate cancer treated with Lu-177 PSMA, spearheaded by @AJangMD @MayoCancerCare @MayoUrology
Ab#5068 @ASCO #ASCO26 by @AJangMD👉 bit.ly/4dB4bNx👉Plasma-derived extracellular vesicles (EVs) in 123 pts w/ mPC treated w/ Lu-177 #prostatecancer➡️CEACAM5 + TROP2 EV composite best predicted PSA50 response (OR 2.96)👇 @flscientist @oncoalert @urotoday @PCF_science
Fabrice Lucien, PhD retweeted
Mayo Clinic Urology was honored to host visiting professor Dr. Hashim Ahmed for a discussion on advances in prostate cancer screening, precision diagnosis, and focal therapy.
#ProstateCancer #FocalTherapy @imperialcollege @LondonProstate1 @SBoorjian @DerekLomas
We are excited to welcome Dr. Hashim U. Ahmed to @MayoClinic as the upcoming James H. DeWeerd Visiting Professorship in Urology in Rochester, MN! @LondonProstate1 @IP_London #VisitingProfessor #Urology #Innovation
Fabrice Lucien, PhD retweeted
Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial (Study Protocol)
bjui-journals.onlinelibrary.…
BRIO is a prospective randomized trial evaluating whether immediate salvage radiotherapy (SRT) ☢️ improves outcomes versus observation with delayed image-guided treatment in men with biochemical recurrence after radical prostatectomy who have negative mpMRI and PSMA-PET/CT imaging.
The study will enroll 312 patients with PSA 🧪 0.2–1.5 ng/mL and assess distant recurrence-free survival, quality of life, adverse effects, and biomarker development to clarify optimal management of imaging-negative recurrent #ProstateCancer after surgery overall
@DrStish @JakeOrmeMDPhD @vidit_sharma_ @JackAndrewsMD @flscientist
@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists
Fabrice Lucien, PhD retweeted
What a day it has been!!!
@AaronNewmanLab and I started this journey years ago back when we were both junior faculty. A difficult question — Can we perform liquid biopsy of the tumor microenvironment?
Spoiler alert. We finally did it! In @Nature & on @CNN today w/ @jaketapper!!
Meet the Locals at #ISEV2026 - learning about the EV research done in Puerto Rico
Dr. Olivier De Jong from Utrecht University with an outstanding talk on EV engineering to allow gene editing in recipient cells. #ISEV2026
Our talented collaborator Dr. Ishwor Thapa, bioinformatician and data scientist at UNO, presenting an important comparative analysis of total and small RNAseq for EV biomarker discovery.
#ISEV2026
Dr. Marca Wauben takes the stage to talk about the relationship between EV cargo and function. #ISEV2026
